These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8526187)

  • 21. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
    Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-interferon combination therapy of resistant myeloma.
    Alexanian R; Barlogie B; Gutterman J
    Am J Clin Oncol; 1991 Jun; 14(3):188-92. PubMed ID: 2031504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma.
    Kars A; Celik I; Kansu E; Tekuzman G; Ozişik Y; Güler N; Barişta I; Güllü I; Yalçin S; Altundağ K; Zengin N; Türker A; Hayran M; Baltali E; Firat D
    Eur J Haematol; 1997 Aug; 59(2):100-4. PubMed ID: 9293857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [VAD chemotherapy of multiple myeloma].
    Amano M; Itoh K; Togawa A
    Rinsho Ketsueki; 1990 Jul; 31(7):917-21. PubMed ID: 2214189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
    Segeren CM; Sonneveld P; van der Holt B; Vellenga E; Croockewit AJ; Verhoef GE; Cornelissen JJ; Schaafsma MR; van Oers MH; Wijermans PW; Fibbe WE; Wittebol S; Schouten HC; van Marwijk Kooy M; Biesma DH; Baars JW; Slater R; Steijaert MM; Buijt I; Lokhorst HM;
    Blood; 2003 Mar; 101(6):2144-51. PubMed ID: 12456509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
    Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
    Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma.
    Porter CA; Rifkin RM
    Clin Lymphoma Myeloma; 2007 Apr; 7 Suppl 4():S150-5. PubMed ID: 17562253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VAD chemotherapy as remission induction for multiple myeloma.
    Anderson H; Scarffe JH; Ranson M; Young R; Wieringa GS; Morgenstern GR; Fitzsimmons L; Ryder D
    Br J Cancer; 1995 Feb; 71(2):326-30. PubMed ID: 7841049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.
    Giles FJ; Wickham NR; Rapoport BL; Somlo G; Lim SW; Shan J; Lynott AM
    Am J Hematol; 2000 Mar; 63(3):125-30. PubMed ID: 10679801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.
    Zervas K; Mihou D; Katodritou E; Pouli A; Mitsouli CH; Anagnostopoulos A; Delibasi S; Kyrtsonis MC; Anagnostopoulos N; Terpos E; Zikos P; Maniatis A; Dimopoulos MA;
    Ann Oncol; 2007 Aug; 18(8):1369-75. PubMed ID: 17693650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
    Berenson JR; Crowley JJ; Grogan TM; Zangmeister J; Briggs AD; Mills GM; Barlogie B; Salmon SE
    Blood; 2002 May; 99(9):3163-8. PubMed ID: 11964279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modified vincristine, doxorubicin, and dexamethasone regimen in the treatment of resistant or relapsed chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group study.
    Friedenberg WR; Anderson J; Wolf BC; Cassileth PA; Oken MM
    Cancer; 1993 May; 71(10):2983-9. PubMed ID: 8490825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report.
    Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S
    Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
    Segeren CM; Sonneveld P; van der Holt B; Baars JW; Biesma DH; Cornellissen JJ; Croockewit AJ; Dekker AW; Fibbe WE; Löwenberg B; van Marwijk Kooy M; van Oers MH; Richel DJ; Schouten HC; Vellenga E; Verhoef GE; Wijermans PW; Wittebol S; Lokhorst HM
    Br J Haematol; 1999 Apr; 105(1):127-30. PubMed ID: 10233375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data.
    Tsiara SN; Kapsali E; Christou L; Panteli A; Pritsivelis N; Bourantas KL
    Eur J Haematol; 2000 Aug; 65(2):118-22. PubMed ID: 10966172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
    Adam Z; Elbl L; Vorlícek J; Hájek R; Tomíska M; Hejlová N; Králová E; Novotná H
    Vnitr Lek; 1994 Aug; 40(8):506-12. PubMed ID: 7941437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
    Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N
    Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
    Weber D; Dimopoulos M; Sinicrope F; Alexanian R
    Leuk Lymphoma; 1995 Sep; 19(1-2):159-63. PubMed ID: 8574163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
    Chen RA; Tu Y; Cao Y; Liu L; Liang Y
    J Int Med Res; 2011; 39(5):1975-84. PubMed ID: 22118002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.